Assessment of syndecan-1 (CD138) and Ki-67 expression for differentiating keratoacanthoma and squamous cell carcinoma

Journal of Drugs in Dermatology

Volumn 12, Issue 3, 2013, Pages

  Lammoglia Ordiales, Lorena ^a   Dominguez Cherit, Judith ^a   Rivera Macías, Samantha ^b   Rodriguez Carreón, Alma A ^a   Fonte Avalos, Verónica ^a   Contreras Barrera, Martha ^a   Toussaint Caire, Sonia ^a  

^a HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; SYNDECAN 1;

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATOACANTHOMA; PREDICTIVE VALUE; PROTEIN EXPRESSION; RISK FACTOR; SKIN; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TISSUE SECTION; TUMOR CELL; TUMOR DIFFERENTIATION;

BIOPSY; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATOACANTHOMA; KI-67 ANTIGEN; SKIN NEOPLASMS; SYNDECAN-1;

EID: 84874618598     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Basal Cell and Squamous Cell Skin Cancers. NCCN Clinical Practice Guidelines in Oncology 2009. http://www.nccn.org/professionals/physician-gls/ pdf/nmsc.pdf. Accessed January 29, 213.
2. Ackerman AB. Squamous-cell carcinoma vs. keratoacanthoma. J Dermatol Surg Oncol. 1982;8(6):418.
3. Arenas R. Carcinoma espinocelular. In: Dermatología - Atlas Diagnóstico Y Tratamiento. 2nd ed. México: McGraw-Hill Interamericana, 2007:141-143.
4. Beham A, Regauer S, Soyer HP, Beham-Schmid C. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol. 1998;5(5):269-280.
5. Epstein EH Jr, Epstein EH. Keratoacanthoma recurrent after surgical excision. J Dermatol Surg Oncol. 1978;4(7):524-525. (Pubitemid 8390528)
6. Griffiths RW. Keratoacanthoma observed. Br J Plast Surg. 2004;57(6):485-501. (Pubitemid 39145148)
7. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous- cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15(4):332-342.
8. Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol. 2007;46(7):671-678. (Pubitemid 47046182)
9. Sachs DL, Marghoob AA, Halpern A. Skin cancer in the elderly. Clin Geriatr Med. 2001;17(4):715-738. (Pubitemid 33032508)
10. Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg. 2004;30(2 Pt 2):326-333. (Pubitemid 38313991)
11. Sullivan JJ. Keratoacanthoma: the Australian experience. Australas J Dermatol. 1997;38(Suppl 1):S36-S39.
12. Freedberg IM, Eisen AZ, Wolff K, et al. Management of basal and squamous cell carcinoma. In: Fitzpatrick's Dermatology in General Medicine. 6th ed. New York: McGraw-Hill, 2003.
13. Thomas P. Habif. Premalignant and malignant nonmelanoma skin tumors. In: Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 4th ed. Philadelphia, PA: Mosby; 2004.
14. Weedon D, Malo J, Brooks D, Williamson R. Keratoacanthoma: is it really a variant of squamous cell carcinoma? ANZ J Surg. 2010;80(3):129-130.
15. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology. 1999;199(3):208-212.
16. Bernfield M, Götte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729-777. (Pubitemid 29449208)
17. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J. 1997;1;327(Pt 1):1-16. (Pubitemid 27455453)
18. Kopper L, Sebestyén A, Gallai M, Kovalszky I. Syndecan-1 - A new piece in B-cell puzzle. Pathol Oncol Res. 1997;3(3):183-191.
19. Inki P, Gomez M, Quintanilla M, Cano A, Jalkanen M. Expression of syndecan in transformed mouse keratinocytes. Lab Invest. 1992;67(2):225-233.
20. Inki P, Larjava H, Haapasalmi K, Miettinen HM, Grenman R, Jalkanen M. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. Eur J Cell Biol. 1994;63(1):43-51. (Pubitemid 2039154)
21. Liebersbach BF, Sanderson RD. Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem. 1994;269(31):20013-20019. (Pubitemid 24250921)
22. Mukunyadzi P, Sanderson RD, Fan CY, Smoller BR. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma. Mod Pathol. 2002;15(1):45-49. (Pubitemid 34081458)
23. Anttonen A, Kajanti M, Heikkila P, Jalkanen M, Joensuu H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer. 1999;79(3-4):558-564. (Pubitemid 29046236)
24. Bologna-Molina R, González-Gonzalez R, Mosqueda-Taylor A, Molina- Frechero N, Damián-Matsumura P, Dominguez-Malagón H. Expression of syndecan-1 in papillary carcinoma of the thyroid with extracapsular invasion. Arch Med Res. 2010;41(1):33-37.
25. Martínez A, Spencer ML, Brethauer U, Grez P, Marchesani FJ, Rojas IG. Reduction of syndecan-1 expression during lip carcinogenesis. J Oral Pathol Med. 2009;38(7):580-583.
26. Stepp MA, Pal-Ghosh S, Tadvalkar G, et al. Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis. Mol Carcinog. 2010;49(4):363-373.
27. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710-1715. (Pubitemid 14035254)
28. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol. 1990;1(3):199-206.
29. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-322. (Pubitemid 30054364)
30. Saǧol O, Kurtoǧlu B, Ozer E, Pabuççuoǧ lu U. Stereological estimation of mean nuclear volume and staining pattern of Ki-67 antigen in keratoacanthomas and squamous cell carcinomas. Gen Diagn Pathol. 1998;143(5- 6):305-309. (Pubitemid 28242970)
31. Bayer-Garner IB, Sanderson RD, Smoller BR. Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma. J Cutan Pathol. 1999;26(8):386-390. (Pubitemid 29486321)
32. Connolly M, Narayan S, Oxley J, de Berker DA. Immunohistochemical staining for the differentiation of subungual keratoacanthoma from subungual squamous cell carcinoma. Clin Exp Dermatol. 2008;33(5):625-628.